Commentary: non-alcoholic fatty pancreas -- toward an uncharted territory; authors' reply

Affiliations

Comment

N S Patel et al. Aliment Pharmacol Ther. 2013 May.

. 2013 May;37(9):916-7.

doi: 10.1111/apt.12280.

¹ Division of Internal Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.

No abstract available

Comment on

Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography.
Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Woo J, Chan FK, Chan HL. Wong VW, et al. Gut. 2012 Mar;61(3):409-15. doi: 10.1136/gutjnl-2011-300342. Epub 2011 Aug 16. Gut. 2012. PMID: 21846782
Commentary: non-alcoholic fatty pancreas -- toward an uncharted territory.
Kwok R, Wong VW. Kwok R, et al. Aliment Pharmacol Ther. 2013 May;37(9):916. doi: 10.1111/apt.12275. Aliment Pharmacol Ther. 2013. PMID: 23551157 No abstract available.

1. Patel NSPM, Brenner DA, Heba E, Sirlin C, Loomba R. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013 (in press). - PMC - PubMed
1. Le TA, Chen J, Changchien C, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial. Hepatology. 2012;56:922–932. - PMC - PubMed
1. Permutt Z, Le TA, Peterson MR, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012;36:22–29. - PMC - PubMed
1. Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56:943–951. - PMC - PubMed